维奈托克与去甲基化药物在不适合强化化疗或难治/复发的急性髓系白血病患者中的真实生活经验：一项单中心经验。
Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.
作者信息
Roldán Pérez Alicia, Vázquez Paganini Juan Andrés, Penalva Moreno M José, Giménez Mesa Eugenio, Vilches Moreno Alba Sara, Nuñez-Torrón Stock Claudia, Herráez García Regina
机构信息
Department of Hemotherapy and Haematology Hospital Universitario Infanta Sofia San Sebastián de los Reyes Spain.
出版信息
Clin Case Rep. 2022 Jul 25;10(7):e6116. doi: 10.1002/ccr3.6116. eCollection 2022 Jul.
Abstract
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well-tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularly when used in patients without prior HMA exposure.
摘要
我们报告了8例急性髓系白血病（AML）患者使用维奈克拉/去甲基化药物（Ven/HMA）的经验，这些患者不适合进行强化化疗或为难治性/复发性患者且治疗选择有限。缓解率为50%。62.5%的患者对维奈克拉耐受性良好。Ven/HMA尤其在未接受过去甲基化药物治疗的患者中使用时具有益处。
相似文献
1
Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.维奈托克与去甲基化药物在不适合强化化疗或难治/复发的急性髓系白血病患者中的真实生活经验：一项单中心经验。
Clin Case Rep. 2022 Jul 25;10(7):e6116. doi: 10.1002/ccr3.6116. eCollection 2022 Jul.
2
The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.维奈托克联合低甲基化剂与 HAG 方案治疗急性髓系白血病患者的疗效：一项回顾性研究。
Hematology. 2024 Dec;29(1):2350319. doi: 10.1080/16078454.2024.2350319. Epub 2024 May 15.
3
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.阿瓦隆研究：关于低甲基化药物联合维奈克拉在新诊断或复发/难治性急性髓系白血病患者中的真实疗效的意大利队列研究。
Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24.
4
Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center.在一家综合癌症中心，成年急性髓系白血病患者使用去甲基化药物联合或不联合维奈克拉的真实世界经验。
World J Oncol. 2023 Feb;14(1):40-50. doi: 10.14740/wjon1557. Epub 2023 Feb 26.
5
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.维奈托克联合低甲基化药物治疗初治 B/髓系混合表型急性白血病和复发/难治性急性髓系白血病：3 例报告。
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
6
Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病青年患者的真实世界研究结果。
Hematology. 2023 Dec;28(1):2265206. doi: 10.1080/16078454.2023.2265206. Epub 2023 Oct 5.
7
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.维奈克拉联合低剂量去甲基化药物或阿糖胞苷治疗复发/难治性急性髓系白血病。
Leuk Lymphoma. 2022 Jul;63(7):1645-1650. doi: 10.1080/10428194.2022.2042688. Epub 2022 Mar 8.
8
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.基因特征可预测复发或难治性急性髓系白血病对维奈克拉联合去甲基化药物的反应。
J Intern Med. 2023 Mar;293(3):329-339. doi: 10.1111/joim.13581. Epub 2022 Nov 3.
9
HMA/VEN treatment modifications and associated outcomes in -mutant AML.HMA/VEN治疗方案调整及与 - 突变型急性髓系白血病相关的结果
Leuk Lymphoma. 2025 Feb;66(2):270-278. doi: 10.1080/10428194.2024.2411436. Epub 2024 Oct 14.
10
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.新诊断的不适合治疗和复发/难治性儿童、青少年和年轻成人急性髓细胞白血病患者中低甲基化剂和 venetoclax 的临床结局。
Br J Haematol. 2024 Sep;205(3):1055-1066. doi: 10.1111/bjh.19679. Epub 2024 Jul 31.
引用本文的文献
1
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?维奈托克治疗现实世界中不适合接受强化化疗的急性髓系白血病患者的系统评价：闪光的都是金子吗？
Ann Hematol. 2025 Feb;104(2):913-935. doi: 10.1007/s00277-024-05891-w. Epub 2024 Aug 16.
2
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.维奈托克联合去甲基化药物治疗希腊既往未治疗的成年急性髓系白血病患者的真实世界多中心经验
J Clin Med. 2024 Jan 19;13(2):584. doi: 10.3390/jcm13020584.
3
Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies.维奈托克联合低甲基化药物治疗新诊断的急性髓系白血病：来自真实世界研究生存数据的系统评价和荟萃分析
Cancers (Basel). 2023 Sep 18;15(18):4618. doi: 10.3390/cancers15184618.
本文引用的文献
1
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.维奈托克在复发或难治性急性髓系白血病患者中的应用：PETHEMA注册研究经验
Cancers (Basel). 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734.
2
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
3
Venetoclax for AML: changing the treatment paradigm.维奈托克治疗急性髓系白血病：改变治疗模式。
Blood Adv. 2019 Dec 23;3(24):4326-4335. doi: 10.1182/bloodadvances.2019000937.
4
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.我们如何将维奈托克与低甲基化剂联合用于治疗新诊断的急性髓系白血病患者。
Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18.
5
Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.维奈托克与低甲基化药物用于治疗TP53基因变异的急性髓系白血病
Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.
6
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Venetoclax 联合低剂量阿糖胞苷治疗未经治疗的急性髓系白血病患者：来自 Ib/II 期研究的结果。
J Clin Oncol. 2019 May 20;37(15):1277-1284. doi: 10.1200/JCO.18.01600. Epub 2019 Mar 20.
7
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.低甲基化药物联合维奈托克治疗急性髓系白血病：临床试验数据更新及实际应用注意事项。
Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.
8
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
9
Acute myeloid leukemia: 2019 update on risk-stratification and management.急性髓细胞白血病：2019 年风险分层和治疗策略更新。
Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214.
10
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
Zotero 插件